EU regulator: Morning-after pill OK for all women

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't work in women weighing more than 80 kilograms (176 pounds).

Last November, HRA Pharma changed the labels on its morning-after pill Norlevo, marketed in 50 countries, saying it was ineffective in women over 80 kilograms after a study of levonorgestrel, one of the drug's active ingredients. Norlevo is not sold in the U.S. but another drug with the same main ingredient, Plan B One-Step, is widely available. The Food and Drug Administration said last year it was reviewing the issue to see if any label changes were needed.

In a statement on Thursday, the EMA said it had assessed all the available evidence and announced the data "are too limited and not robust enough to conclude with certainty" that the pill's efficacy is reduced in heavier women. It said the results of these studies should be included in the product information but that current warnings on Norlevo's packaging should be deleted.

The morning-after pill contains a higher dose of the hormone in regular birth control pills. Taking it within 72 hours of sexual intercourse can cut the chances of pregnancy by up to 89 percent but it works best within the first 24 hours. If a woman is already pregnant, the pill, which prevents ovulation or fertilization, has no effect.

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Medical charity warns India over patent rules

Jan 21, 2015

Doctors without Borders on Wednesday warned the Indian government not to bow to US pressure to amend patent regulations that allow millions access to affordable medicines, ahead of a visit by President Barack Obama.

Why are some generic drugs getting so expensive?

Jan 21, 2015

More than eight out of every 10 prescriptions dispensed in the US is generic. This growth is due to a large number of top-selling drugs going off patent over the past decade, as well as innovations in t ...

Supreme Court sides with Teva in drug dispute

Jan 20, 2015

The Supreme Court on Tuesday sided with Teva Pharmaceutical Industries Ltd. in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.